Recent News

• 06.08.2026 - CNS Pharmaceuticals CFO, Steve O’Loughlin, Highlights Company’s Recent $22.5M Financing in Virtual Investor “What This Means” Segment
• 05.20.2026 - CNS Pharmaceuticals CEO, Rami Levin, Participates in Virtual Investor CEO Connect Segment Highlighting Company’s Recent Strategic Transformation Progress

Recent Filings

• 05.26.2026 - 424B3 Prospectus [Rule 424(b)(3)]
• 05.26.2026 - EFFECT Notice of Effectiveness
• 05.20.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.19.2026 - S-3 Registration statement under Securities Act of 1933
• 05.19.2026 - D Notice of Exempt Offering of Securities
• 05.15.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.14.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.04.2026 - 8-K Current report
• 04.30.2026 - 10-K/A Annual report [Section 13 and 15(d), not S-K Item 405]
• 04.17.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors